This cross-protocol analysis included patients with newly diagnosed , rifampicin-susceptible pulmonary tuberculosis , with and without HIV , enrolled in clinical trials ( who took > 80 % of medication ) at the National Institute for Research in Tuberculosis between 1999 and 2013 .